This ‘hot-blooded’ CEO is aiming to transform the way burn victims heal

Cutiss CEO Daniela Marino is funneling her bold personality and expertise in regenerative medicine into a startup developing bioengineered skin grafts.

By Alexandra Pecci • May 9, 2023

Insulin prices have dropped — will Civica still be a disrupter in the field?

The nonprofit generics maker still sees a need for low-cost insulin despite recent moves by major drugmakers to slash the prices of their popular products. 

By Karissa Waddick • May 8, 2023

Explore the Trendline➔

Commercialization, marketing and social media

As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

By PharmaVoice staff

Woman of the Week: Jazz Pharmaceuticals’ Neena Patil

Patil’s dual interests in healthcare and law are at the intersection of her C-suite role.

By Taren Grom • May 3, 2023

Scientists could finally be closing in on a ‘pill’ for men

Drug developers have tried — and failed — to create a male contraceptive for decades. Now, one group of scientists might be on the verge of success.

By Kelly Bilodeau • April 26, 2023

Woman of the Week: Brii Biosciences’ Ellee de Groot

A chemical engineer by training, Brii’s chief technology officer is applying her experience to solve research problems from the clinic to commercial development.

By Taren Grom • April 19, 2023

Patient influencers are here to stay — where are the regulations?

As social media health influencers enter the world of pharma advertising, experts warn that more guardrails are needed to protect the industry and patients.

By Karissa Waddick • April 17, 2023

What’s pharma doing wrong to improve trial diversity? ‘Everything’

Pharma’s missing the mark when it comes to recruiting Black patients, and Ricki Fairley, CEO of The Black Breast Cancer Alliance, reveals what’s needed.

By Karissa Waddick • April 12, 2023

Woman of the Week: uMotif’s Julia Lakeland

The chief product officer’s work in transforming clinical trial technology is driven by people.

By Taren Grom • April 12, 2023

Where one unicorn struggled, another biotech is aiming for a diabetes win

Intarcia looked poised to break into a lucrative diabetes implant market but has been dogged by safety issues — now Vivani thinks it’s found a way to succeed.

By Kelly Bilodeau • April 10, 2023

GoodRx Health is the one-stop-shop for patients — and marketers

Optimize patient conversion through a single platform with GoodRx: the one-stop-shop for patients — and marketers.

April 10, 2023

5 minutes with — Parexel’s Peyton Howell

The company’s chief operating and growth officer on her personal quirks and why every pharma leader should read "Getting Naked."

By Taren Grom • April 7, 2023

A drug just launched for a disease discovered only 10 years ago

Pharming just landed an FDA approval for a treatment targeting an ultra-rare immunodeficiency disorder discovered only a decade ago — and it’s already in the hands of patients.

By Karissa Waddick • April 6, 2023

Amgen’s aim for a ‘moonshot’ in cardiovascular disease

A VP of global development at Amgen explains how treating general medicine diseases could one day resemble approaches in oncology.  

By Taren Grom • April 5, 2023

All eyes turn to Karuna as it aims for an approval of a would-be blockbuster

In the red-hot race for new schizophrenia treatments, Karuna Therapeutics is close to an FDA submission.

By Kelly Bilodeau • April 3, 2023

Leaders wave a magic wand at pharma’s thorniest issues

The major challenges pharma leaders would solve with a quick flick of an imaginary wand.

By PharmaVoice staff • March 31, 2023

Predator and prey: Harnessing phages to fight antibiotic resistance

Phages, bacteria’s natural predator, could help combat the growing threat of superbugs. But can these therapies rise above antibiotic market woes?

By Karissa Waddick • March 30, 2023

Seamless clinical trials were created to make studies easier — instead, they’ve become more complex

Experts weigh in on how companies can design better trials that merge two phases into one.

By Meagan Parrish • March 29, 2023

What would you fix with a ‘magic wand?’ Pharma leaders chime in about clinical trials

How life science execs would transform clinical trials with a little hocus pocus.

By PharmaVoice staff • March 24, 2023

Everyone says they’re patient-centric, but have they really walked the walk?

Life science leaders provide practical tips on how to create a sustainable patient-focused culture.

By Karissa Waddick • March 23, 2023

Viral roots: A look at how modern outbreaks began

As experts wrestle with COVID-19’s lab leak versus animal market debate, here’s what experts say are the suspected origins for some of the worst viral outbreaks in the last century.

By Meagan Parrish • March 22, 2023

‘The Last of Us’ might be fiction, but fungi are a looming threat

Fungal infections are a growing challenge for hospitalized patients, and new treatments are badly needed.

By Kelly Bilodeau • March 20, 2023

A biopharma CEO’s quest for global health equity has put him in the running for a Nobel Prize

Dr. Ryan Saadi, CEO of Tevogen Bio, is making good on a lifelong goal of bringing T cell therapies to people who need them.

By Taren Grom • March 17, 2023

In the fallout from Aduhelm, Biogen’s leadership shakeup continues

The recent departure of neurodegenerative development head Samantha Budd Haeberlein is just the latest sign of a changing tide among Biogen’s post-Aduhelm leadership.

By Karissa Waddick • March 16, 2023

The power of connections for a startup CEO

Priyanka Dutta-Passecker, head of wound-care specialist Healiva, discusses the importance of tapping her network in starting and running a biotech.

By Alexandra Pecci • March 14, 2023

Babson aims to shed Theranos curse with new blood testing tech

Babson Diagnostics is trying to create a less invasive blood testing technology — can it gain trust in the post-Theranos era?

By Kelly Bilodeau • March 13, 2023